Wendy Adams

As Research Grant Director and member of the Advisory Board, she leads their research grant strategy. Wendy is also an active member of the Board of Directors for the Lyme Disease Biobank. Her unique perspective and knowledge as a former Lyme patient—as well as her background in product development and business strategy for companies like Cowen, Genentech and Aviron—make her skillset valuable to BAL. Wendy has spent over 20 years in the biotechnology field and most recently served as Chief Business Officer at Full Spectrum Genetics, Inc., an antibody engineering company pursuing programs in immuno-oncology and autoimmune disease. Previously, she ran B2DC LLC, a business development consultancy to biotech clients in infectious and autoimmune disease, therapeutic and prophylactic vaccines, oncology, drug delivery and neurology. Wendy holds an MBA from the Haas School of Business, University of California at Berkeley, where she also served on the faculty in Entrepreneurship, and an AB from Duke University. She served as a member or subcommittee member of the HHS Tick Borne Disease Working Group Federal Advisory Committee from 2017-2020 and currently serves as a Programmatic Reviewer for the Department of Defense Congressionally Directed Medical Research Program in Tick-Borne Disease. She also serves on the Lyme Disease Advisory Committee for the California Department of Public Health.